Investment Analysts’ Weekly Ratings Updates for Retension Pharmaceuticals (RTSN)

Several analysts have recently updated their ratings and price targets for Retension Pharmaceuticals (NASDAQ: RTSN):

  • 11/14/2026 – Retension Pharmaceuticals was upgraded by Wall Street Zen to “hold”.
  • 11/4/2026 – Retension Pharmaceuticals is now covered by Zacks Research. They set a “hold” rating on the stock.
  • 11/3/2026 – Retension Pharmaceuticals is now covered by Leerink Partners. They set a “strong-buy” rating on the stock.
  • 11/3/2026 – Retension Pharmaceuticals is now covered by Oppenheimer. They set an “outperform” rating and a $50.00 price target on the stock.
  • 11/2/2026 – Retension Pharmaceuticals is now covered by Guggenheim. They set a “buy” rating and a $55.00 price target on the stock.

Retension Pharmaceuticals Stock Performance

Shares of Retension Pharmaceuticals stock traded down $0.44 during trading hours on Thursday, hitting $13.45. 28,902 shares of the company’s stock traded hands, compared to its average volume of 121,190. Retension Pharmaceuticals, Inc. has a twelve month low of $9.66 and a twelve month high of $18.64.

Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) last posted its quarterly earnings results on Wednesday, November 18th. The company reported ($7.33) earnings per share (EPS) for the quarter. As a group, analysts predict that Retension Pharmaceuticals, Inc. will post -6.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Eric Keller purchased 20,800 shares of the firm’s stock in a transaction on Tuesday, October 13th. The stock was purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the purchase, the chief executive officer owned 423,377 shares in the company, valued at $5,080,524. This trade represents a 5.17% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Franklin Berger bought 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 13th. The stock was acquired at an average price of $12.00 per share, for a total transaction of $120,000.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $120,000. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure.

We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.

Featured Stories

Receive News & Ratings for Retension Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.